Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024623 (
gastric cancer
)
36,219
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
COX (cyclooxygenase) is one of the key enzymes involved in the synthesis of a variety of prostaglandins (PGs), some of which have been strongly linked to inflammation. One of its two well-known isoforms,
COX-2
, is an inducible enzyme whose induction and expression is dynamically regulated by growth factors, mitogens, and tumor promoters. Several animal and clinical studies have reported the chemopreventive effect of celecoxib, a selective
COX-2
inhibitor; and in particular, a few studies have shown that celecoxib prevents the development of
gastric cancer
. Administration of celecoxib also showed increases in cardiovascular risk and disruption of renal physiology. Therefore, studies hoping to clarify how selective
COX-2
inhibitors modulate
gastric cancer
must keep in mind that coxibs have also been linked to serious cardiovascular events and disruption of renal physiology.
...
PMID:Chemopreventive effect of celecoxib in gastric cancer. 1732 86
We report the molecular characterization of 8 primary gastric carcinomas, corresponding xenografts, and 2 novel gastric carcinoma cell lines. We compared the tumors and cell lines, with respect to histology, immunohistochemistry, copy number, and hypermethylation of up to 38 genes using methylation-specific multiplex ligation-dependent probe amplification, and TP53 and CDH1 mutation analysis where relevant. The primary tumors and xenografts were histologically comparable and shared expression of 11 of 14 immunohistochemical markers (E-cadherin, beta-catenin,
COX-2
, p53, p16, TFF1, cyclin E, MLH1, SMAD4, p27, KLK3, CASR, CHFR, and DAPK1). Gains of CASR, DAPK1, and KLK3--not yet described in
gastric cancer
--were present in the primary tumors, xenografts, and cell lines. The most prominent losses occurred at CDKN2A (p16), CDKN2B (p15), CDKN1B (p27/KIP1), and ATM. Except for ATM, these losses were found only in the cell line or xenograft, suggesting an association with tumor progression. However, examination of p16 and p27 in 174 gastric cancers using tissue microarrays revealed no significant correlation with tumor stage or lymph node status. Further losses and hypermethylation were detected for MLH1, CHFR, RASSF1, and ESR, and were also seen in primary tumors. Loss of CHFR expression correlated significantly with the diffuse phenotype. Interestingly, we found the highest rate of methylation in primary tumors which gave rise to cell lines. In addition, both cell lines harbored mutations in CDH1, encoding E-cadherin. Xenografts and
gastric cancer
cell lines remain an invaluable research tool in the uncovering of the multistep progression of cancer. The frequent gains, losses, and hypermethylation reported in this study indicate that the involved genes or chromosomal regions may be relevant to gastric carcinogenesis.
...
PMID:Molecular analysis of primary gastric cancer, corresponding xenografts, and 2 novel gastric carcinoma cell lines reveals novel alterations in gastric carcinogenesis. 1737 10
Epidemiologic studies have shown that nonsteroidal anti-inflammatory drugs could reduce the risk of cancer development including
gastric cancer
. This study was performed to identify the antineoplastic mechanism in
gastric cancer
cells affected by celecoxib, a selective
COX-2
inhibitor. MTT assay, ELISA for prostaglandin E(2) (PGE(2)), cell-cycle analyses, immunofluorescent staining, and flow cytometry were performed after treating human
gastric cancer
cell lines (AGS and MKN-45) with celecoxib or indomethacin. The viabilities of celecoxib-treated cells decreased in a dose- and time-dependent manner compared with indomethacin. Drop of PGE(2) levels was more prominent in the presence of indomethacin than in that of celecoxib. Celecoxib arrested the cell cycle in the G(0)-G(1) phase, which reduced cell numbers in the S phase. Moreover, celecoxib increased the apoptotic cell proportions, a 4-fold increase over control cells. The anticancer effects of celecoxib on
gastric cancer
cells appear to be mediated by cell-cycle arrest and apoptosis, and not by
COX-2
or PGE(2) suppression alone.
...
PMID:The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. 1739 25
Over the past year Helicobacter pylori has been confirmed as the most important risk factor for non-cardia gastric adenocarcinomas and gastric mucosa-associated lymphoid tissue (MALT) lymphomas. Eradication therapy has been proven to be beneficial when given prior to the development of intestinal metaplasia, but is less efficacious when administered later. However, the best data from clinical trials indicate that H. pylori eradication alone will have only a moderate effect on
gastric cancer
incidence worldwide. The mechanisms responsible for H. pylori-associated gastric carcinogenesis continue to be dissected. Accumulating evidence suggests that some H. pylori may be able to invade through the gastric epithelial barrier, though pro-carcinogenic effects may also be related to the complex and evolving pathways of altering signal transduction pathways within gastric epithelial cells that are stimulated by adherence and translocation of H. pylori products through its type IV secretory system. Determinants of the host response to H. pylori infection continue to focus on polymorphisms in genes related to the innate and acquired immune responses, including NOD2,
COX-2
, and TLR-4. H. pylori eradication is indicated for low-grade gastric B-cell MALT lymphoma and may even provide "cure" in some apparently H. pylori-negative cases. How and why does H. pylori promote lymphomagenesis? Some evidence from human and murine models points to specific chromosomal translocations and host genetic polymorphisms as relating to the outcome of infection. Finally, Helicobacter hepaticus infection has been linked to both intestinal and breast tumorigenesis in susceptible strains of female mice - a provocative and novel finding warranting further investigation.
...
PMID:Helicobacter and gastric malignancies. 1772 57
Recent studies have reported that expression of MCP-1 and its receptor, CCR2; and CD40-CD40 ligand (CD40L) interaction on mesenchymal cells play important roles in tumor development. Studies have also connected MCP-1, CCR2, and CD40L to
COX-2
expression. The aim of this study was to examine the effect of MCP-1/CCR2 and CD40-CD40L interaction on
COX-2
and VEGF expression in endothelial cells. We also investigated the localization of these proteins in
gastric cancer
tissue.
COX-2
and CCR2 levels were evaluated in CD40L-stimulated HUVECs by Western blot and real-time PCR. VEGF secreted in the culture media was quantified by ELISA. Localizations of MCP-1, CD40L, CD34, CD40 and CCR2 in 34
gastric cancer
tissue specimens were evaluated by immunohistochemistry. CD40-CD40L interaction-induced
COX-2
production and subsequently, upregulated
COX-2
production contributed to elevated VEGF and CCR2 levels in CD40L-stimulated HUVECs. CD40L-stimulated VEGF production was
COX-2
but not COX-1 dependent. RS-102895, a CCR2-specific antagonist, significantly reduced VEGF production in CD40L- and MCP-1-stimulated HUVECs. MCP-1 had a synergistic effect on
COX-2
, CCR2 and VEGF levels in CD40L-stimulated HUVECs. In
gastric cancer
tissue, there was significant correlation between microvessel density and scores for CD40L, MCP-1 and CCR2 protein expression. Thus, MCP-1 had a synergistic effect on
COX-2
and CCR2 protein expression in CD40L-stimulated HUVECs and thereby stimulated VEGF production in these cells.
...
PMID:COX-2 and CCR2 induced by CD40 ligand and MCP-1 are linked to VEGF production in endothelial cells. 1809 16
COX-2
overexpression is known to be an important mechanism in gastric carcinogenesis. Previously we have found that early-onset
gastric cancer
has a unique
COX-2
low-expressing phenotype that differs significantly from that of the frequent overexpression seen in conventional gastric cancers. To investigate whether the
COX-2
-765 G>C promoter polymorphism (known to lead to a reduction of
COX-2
promoter activity in the colon) may explain this difference in expression, we carried out single-nucleotide polymorphism (SNP) analysis of 241 gastric cancers, including early-onset
gastric cancer
, conventional gastric cancers and gastric stump cancers, as well as in 100 control patients, using real-time PCR and sequence analysis, and correlated these findings with
COX-2
expression using immunohistochemistry. We found that the C allele was present in 30% of early-onset gastric cancers, 24% of conventional
gastric cancer
, 23% of stump cancers, in contrast to 41% in the control group. There was a statistically significant difference in the presence of the C allele in patients with
gastric cancer
compared with the control group (P=0.007), with the C allele being associated with protection against
gastric cancer
. However, there was no significant difference between the early-onset, conventional and stump
gastric cancer
groups. Interestingly, there was no correlation between the presence of the C allele and a difference in
COX-2
expression. In summary, we show that the
COX-2
-765 G allele promoter polymorphism is significantly associated with
gastric cancer
when compared with the normal control group, but does not appear to be related directly to
COX-2
expression pattern in
gastric cancer
. Although early-onset gastric cancers appear to have a unique
COX-2
expression pattern when compared with conventional
gastric cancer
, the exact mechanism by which this occurs is yet to be elucidated.
...
PMID:The COX-2 promoter polymorphism -765 G>C is associated with early-onset, conventional and stump gastric cancers. 1831 Nov 13
To identify the role of eicosanoid-mediated pathways for gastric carcinogenesis, the expression of enzymes (COX-1,
COX-2
, 5-LOX) and receptors (BLT-1, CysLTR(1)) were immunohistochemically studied in H. pylori positive patients with a risk gastritis phenotype and either successful or unsuccessful eradication (n=12, each; followed up for a median of 5 years).
Gastric cancer
risk index improved significantly after successful eradication (p<0.001). Semiquantitative immunohistochemistry revealed distinct significant changes in the expression patterns for
COX-2
, CysLTR1, COX-1 and BLT-1 depending on the eradication outcome, whereas 5-LOX expression was not altered. These results suggest an involvement of the COX-LOX pathway in gastric carcinogenesis.
...
PMID:The long-term effect of Helicobacter pylori eradication on COX-1/2, 5-LOX and leukotriene receptors in patients with a risk gastritis phenotype--a link to gastric carcinogenesis. 1857 38
Cyclooxoygenase (COX)-2 overexpression is involved in gastric carcinogenesis. While high-salt intake is a known risk factor for
gastric cancer
development, we determined the effects of high salt on gastric chemical carcinogenesis in
COX-2
transgenic (TG) mice.
COX-2
TG mice were developed in C57/BL6 strain using the full-length human cox-2 complementary DNA construct. Six-week-old
COX-2
TG and wild-type (WT) littermates were randomly allocated to receive alternate week of N-methyl-N-nitrosourea (MNU, 240 p.p.m.) in drinking water or control for 10 weeks. Two groups of mice were further treated with 10% NaCl during the initial 10 weeks. All mice were killed at the end of week 50. Both forced
COX-2
overexpression and high-salt intake significantly increased the frequency of
gastric cancer
development in mice as compared with WT littermates treated with MNU alone. However, no additive effect was observed on the combination of high salt and
COX-2
expression. We further showed that MNU and high-salt treatment increased chronic inflammatory infiltrates and induced prostaglandin E(2) (PGE(2)) production in the non-cancerous stomach. Whereas high-salt treatment markedly increased the expression of inflammatory cytokines (tumor necrosis factor-alpha, interferon-gamma, interleukin (IL)-1 beta and IL-6) in the gastric mucosa,
COX-2
overexpression significantly altered the cell kinetics in the MNU-induced
gastric cancer
model. In conclusion, both high salt and
COX-2
overexpression promote chemical-induced gastric carcinogenesis, possibly related to chronic inflammation, induction of PGE(2), disruption of cell kinetics and induction of inflammatory cytokines.
...
PMID:Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. 1861 16
Cyclo-oxygenase (COX) profile predicts prognosis of
gastric cancer
;
COX-2
positive tumors are more often aggressive, and
COX-2
suppression is protective against
gastric cancer
. In contrast, COX-1 suppression is harmful to the intestinal mucosa. The COX-1,
COX-2
, and COX-1ir expression profiles were measured with real-time PCR in primary (AGS) and metastatic (NCI-N87) gastric adenocarcinoma cell lines treated with butyrate, hyperosmolar medium, and, in the case of NCI-N87, cell-free supernatants of probiotic bacteria Lactobacillus acidophilus 74-2 and Bifidobacterium lactis 420. The cell lines showed differences in the profile when treated with either hyperosmolar medium or butyrate. In NCI-N87
COX-2
expression was higher but only COX-1 expression was significantly upregulated by butyrate. Similarly to butyrate, the cell-free supernatant of L. acidophilus 74-2 upregulated COX-1, while
COX-2
expression remained unchanged. COX-1ir, including COX-3, was upregulated by probiotics and osmotic stress. In conclusion, consumption of L. acidophilus 74-2 could be beneficial for the expression of cytoprotective COX-1.
...
PMID:Lactobacillus acidophilus 74-2 and butyrate induce cyclooxygenase (COX)-1 expression in gastric cancer cells. 1861 13
The over-expression of
COX-2
(Cyclooxygenase 2) protein has been reported to play a key role in the incidence and development of Helicobacter pylori-associated
gastric cancer
. The induction of
COX-2
in the
gastric cancer
cells with H. pylori has been demonstrated previously, but little is known about the mechanism. This study reported that the
COX-2
mRNA and proteins expression level and the activity of
COX-2
promoter increased remarkably with H. pylori stimulation in the MKN45
gastric cancer
cells. H. pylori also stimulated phosphorylation of p38MAPK and ATF-2, which is the downstream kinase of p38MAPK. Moreover, the expression levels of
COX-2
were suppressed with p38MAPK inhibitor treatment. These results suggest that H. pylori-induced activation of p38MAPK/ATF-2-mediated signal pathway is necessary for the expression of
COX-2
.
...
PMID:Helicobacter pylori enhances cyclooxygenase 2 expression via p38MAPK/ATF-2 signaling pathway in MKN45 cells. 1920 Oct 83
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>